Kalvista Pharmaceuticals Stock Investor Sentiment

KALV Stock  USD 11.89  0.11  0.92%   
Slightly above 69% of Kalvista Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Kalvista Pharmaceuticals suggests that many traders are alarmed. Kalvista Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Kalvista Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  

Kalvista Pharmaceuticals Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Kalvista Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Kalvista Pharmaceuticals Maximum Pain Price Across June 20th 2025 Option Contracts

Kalvista Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Kalvista Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Kalvista Pharmaceuticals' options.
a day ago at news.google.com         
Technical Pivots with Risk Controls - Stock Traders Daily
Google News at Macroaxis
few days ago at www.macroaxis.com         
Acquisition by Benjamin Palleiko of 9363 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
few days ago at news.google.com         
H.C. Wainwright maintains Buy on Kalvista, 20 target - Investing.com
Google News at Macroaxis
over a week ago at www.macroaxis.com         
Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over a week ago at thelincolnianonline.com         
Needham Company LLC Reaffirms Buy Rating for KalVista Pharmaceuticals
news
over a week ago at thelincolnianonline.com         
Disposition of 2187 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 9.8702 subject to Rule 1...
news
over a week ago at news.google.com         
KALVISTA PHARMACEUTICALS Earnings Results KALV Reports Quarterly Earnings - Nasdaq
Google News at Macroaxis
over a week ago at thelincolnianonline.com         
KalVista Pharmaceuticals, Inc. CEO Benjamin L. Palleiko Sells 6,669 Shares
news
over a week ago at finance.yahoo.com         
KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and...
Yahoo News
over two weeks ago at www.macroaxis.com         
Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule...
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over two weeks ago at www.macroaxis.com         
Disposition of 12084 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over two weeks ago at finance.yahoo.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
Yahoo News
over two weeks ago at thelincolnianonline.com         
Brokerages Set KalVista Pharmaceuticals, Inc. PT at 23.80
news
over two weeks ago at businesswire.com         
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
businesswire News
Far too much social signal, news, headlines, and media speculation about Kalvista Pharmaceuticals that are available to investors today. That information is available publicly through Kalvista media outlets and privately through word of mouth or via Kalvista internal channels. However, regardless of the origin, that massive amount of Kalvista data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Kalvista Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Kalvista Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Kalvista Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Kalvista Pharmaceuticals alpha.

Kalvista Pharmaceuticals Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
01/30/2025
2
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 11754 shares of Kalvista Pharmaceuticals at 8.89 subject to Rule 16b-3
02/03/2025
3
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 73649 shares of Kalvista Pharmaceuticals at 9.29 subject to Rule 16b-3
02/07/2025
4
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 26703 shares of Kalvista Pharmaceuticals at 9.18 subject to Rule 16b-3
02/11/2025
5
Acquisition by Venrock Healthcare Capital Partners Iii, L.p. of 100000 shares of Kalvista Pharmaceuticals at 9.23 subject to Rule 16b-3
02/12/2025
6
Disposition of 2419 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3
02/14/2025
7
Disposition of 5104 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 9.8242 subject to Rule 16b-3
02/18/2025
8
Acquisition by Christopher Yea of 4204 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
02/19/2025
9
KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting
02/21/2025
10
Disposition of 1918 shares by Christopher Yea of Kalvista Pharmaceuticals at 10.02 subject to Rule 16b-3
02/24/2025
11
Disposition of 2394 shares by Audhya Paul K. of Kalvista Pharmaceuticals at 10.02 subject to Rule 16b-3
02/25/2025
12
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma Immunology 2025 Annual Meeting
03/03/2025
13
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635
03/04/2025
14
Disposition of 12084 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3
03/05/2025
15
Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3
03/06/2025
16
Disposition of 6669 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 11.97 subject to Rule 16b-3
03/07/2025
17
KalVista Pharmaceuticals, Inc. CEO Benjamin L. Palleiko Sells 6,669 Shares
03/11/2025
18
Needham Company LLC Reaffirms Buy Rating for KalVista Pharmaceuticals
03/13/2025
19
Acquisition by Benjamin Palleiko of 30195 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
03/14/2025
20
Acquisition by Benjamin Palleiko of 9363 shares of Kalvista Pharmaceuticals subject to Rule 16b-3
03/18/2025

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.